Objective: To study the impact of rising bilateral mastectomy rates among neoadjuvant chemotherapy (NAC) recipients in California. Background: NAC for operable breast cancer (BC) can downstage disease and facilitate breast conservation. We assessed trends in NAC use and surgical procedures in California from January 1, 1998 to December 31, 2012 using statewide population-based cancer registry data. Methods: A total of 236,797 females diagnosed with stage I-III BC were studied. Information regarding NAC, adjuvant chemotherapy (aCT), breast conserving surgery (BCS), bilateral mastectomy (BLM), and unilateral mastectomy (ULM) was abstracted from the medical records. Multivariable polytomous logistic regression was used to estimate odds ratios (OR) of receiving NAC and of type of surgery after NAC. Multivariable predictors of NAC treatment were stage (III), younger age (<40 yrs), Black or Hispanic race/ethnicity versus non-Hispanic White (OR 1.10, 95% confidence interval (CI) 1.05-1.16), and care at a National Cancer Institute (NCI)-designated center (OR 1.70, CI 1.58-1.82). Most NAC recipients (68.4%) had mastectomies, and 14.3% of them underwent BLM. In contrast, 47.9% aCT patients had mastectomies with 7.3% BLM. The only independent predictor of BCS after NAC was care at a NCI-designated center (OR 1.28, CI 1.10-1.49), and of BLM, age <40 years versus 50 to 64 years (OR 2.59, CI 2.21-3.03), or residence in the highest socioeconomic neighborhood quintile versus lowest (OR 2.10, CI 1.67-2.64). Conclusions: NAC use remains low. Predictors of surgery type after NAC were sociodemographic rather than clinical, raising concern for disparities in care access.
T he benefits of neoadjuvant chemotherapy (NAC) for breast cancer (BC) are multifaceted: providing insight into chemosensitivity, facilitating breast conservation, and delivering unique prognostic information. NAC use is on the rise as reflected in recent statistics from the National Cancer Database. 1 Long-term follow up has shown consistent and equivalent overall survival between adjuvant (postoperative) chemotherapy (aCT) and NAC treatment groups, proving that surgical delay for systemic therapy is not detrimental. Moreover, NAC provides an in vivo test that discriminates between treatment responders and nonresponders, and yields unique prognostic information based on residual cancer burden. 2 Furthermore, re-evaluation of tumor biomarkers or genomic profiling may guide post-NAC therapies.
A practical aspect of NAC is disease down-staging. Lumpectomy use increased by 12% in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-18 protocol, the first randomized comparison of aCT with NAC in palpable, operable BC. 3 These observations have since been corroborated in a subsequent pooled analysis. 4 Moreover, initiating chemotherapy before surgery has been associated (albeit nonsignificantly) with better survival in younger women (age <50 yrs at diagnosis). 5 As the neoadjuvant approach has gained acceptance, surgeons and radiation oncologists have been challenged to adapt the use of sentinel node biopsy, and to reconsider regional radiation in this patient population. [6] [7] [8] [9] [10] Another benefit of NAC is that it enables faster evaluation of drug regimens compared to the same treatments given adjuvantly. Consequently, the United States Food and Drug Administration (FDA) recently accepted tumor response to NAC as a drug approval endpoint,with pertuzumab the first agent thus approved. 4, 11, 12 Implementing NAC requires multidisciplinary coordination between surgeons and medical oncologists at the time of initital diagnosis and therefore its prevalence in mainstream practice is largely unknown. We and others recently reported a substantial rise in use the use of bilateral mastectomy (BLM, unilateral therapeutic with contralateral 
METHODS

Case Ascertainment and Data Collection
The study population included all female California residents diagnosed with a first primary breast cancer of American Joint Commission on Cancer (AJCC) stages I-III from January 1, 1998 through December 31, 2012. International Classification of Diseases for Oncology, third edition (ICD-0-3) site codes C50.0-C50.9 were used excluding any breast tumors with hematopoietic, mesothelioma, or Kaposi's sarcoma histologic codes (ICD-O-3 morphology codes 9050-9055, 9140, 9590-9992). This human subject research was approved as part of the Cancer Prevention Institute of California Institutional Review Board's cancer registry protocol. We used CCR data routinely abstracted from medical records regarding patient age at diagnosis, race/ethnicity, marital status, stage, tumor grade, size and histology, lymph node involvement, metastasis, tumor molecular markers including estrogen receptor, progesterone receptor and HER2, first course of treatment (surgery, chemotherapy including its timing in relation to surgery, and radiation therapy), primary health insurance, and residence (Census block group) at diagnosis. 17 
Tumor and Lymph Node Staging
According to SEER protocol, AJCC stage is derived from reported tumor size (T), lymph node (N), and metastasis (M) components. 17 From 1998 to 2003, clinical tumor size was reported for NAC recipients (clinical staging). Nodal status, however, was represented by the highest reported N stage at any time. For example, node-negative status by pathologic staging after surgery would be entered according to the higher clinical staging if nodes were involved before NAC. 17 In the timeframe of 2004 to 2012, both T and N stages were the highest stages reported, and the distribution of staging method among NAC-treated patients is shown in the Supplemental Table, 
Neighborhood-level Information
We used a previously developed measure of the neighborhood socioeconomic status (nSES) based on patients' residence at the time of cancer diagnosis. For cases diagnosed during 1998 to 2005, this measure comprised quintiles based on the statewide distribution of census block groups from the 2000 Census on education, housing costs, income, and occupation. 18 For cases diagnosed from 2006 to 2012, we used the 2007-2011 American Community Survey of the US Census. 19 Urban-rural designation at the medical service study area (MSSA) based on the 2000 and 2010 Census was included.
Hospital-level Information
The CCR records the institution that first reports each cancer case, which is the treating facility for the great majority (94.8%) of cases. 17 For each facility, we determined the nSES distribution of all cases, and identified facilities that were NCI-designated cancer centers.
Statistical Analysis
We used multivariable logistic regression to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the association of patient, tumor, sociodemographic, and facility characteristics with receipt of NAC versus no receipt of NAC. The following variables were included in the model: age, race/ethnicity, diagnosis year, stage, histology, grade, lymph node involvement, hormone receptor status, marital status, primary insurance, nSES, the reporting hospital's NCI-designation status, and nSES distribution of patients. As HER2 data were missing in 41% of cases diagnosed before 2005, we constructed a model including HER2 status, limited to patients for whom it was known. Polytomous logistic regression was used to model surgical procedure after NAC, with unilateral mastectomy as the referent procedure. All analyses were conducted using SAS 9.3 (Cary, NC).
RESULTS
Patient Characteristics
A total of 253,986 stage I-III breast cancer cases were diagnosed and reported to CCR from January 1, 1998 to December 31, 2012, of which 236,797 were considered eligible (Supplemental Figure 1 , http://links.lww.com/SLA/B88). Patients with a metachronous contralateral breast cancer (N ¼ 5690, 2.4%) were not excluded; however, only the breast surgery undertaken for treatment of the first cancer was analyzed and in the case of mastectomy, was counted as a ULM. BLMs reported here pertain only to mastectomy treatment for the cancer-affected breast with a contralateral prophylactic mastectomy (CPM). For patients diagnosed from 2004 to 2012, T and N staging (the highest stage reported, as described above) was clinical in 63.9% and pathologic in 36.1%.
Use of Chemotherapy, NAC, and aCT
Among all analyzed patients, 141,817 patients (59.9%) received no chemotherapy, 82,588 patients (34.9%) received aCT, and 12,392 patients (5.2%) received NAC (Tables 1 and 2 ). Considering only chemotherapy recipients (N ¼ 94,980), 87.0% received aCT and 13.0% received NAC. The proportion of patients treated with NAC increased noticeably from 7.9% in 1998 to 18.0% to 20.0% in 2011 to 2012 (Fig. 1) . The ratio of aCT to NAC among chemotherapy recipients was inversely related to stage (Stage I: 96.6% aCTand 3.4% NAC; Stage II: 89.0% aCT and 11.0% NAC; and Stage III: 70.1% aCT and 29.9% NAC). Similar trends are are reflected by tumor size and number of involved nodes (Table 2) .
NAC was used in 8.8% of uninsured or self-pay, 7.1% of public/Medicaid, and 1.9% of Medicare-insured patients. Public/ Medicaid-insured patients had the highest proportional use of NAC (19.1%), followed by 17.9% for not insured/self-pay, 14.2% for military, 11.7% for private, and 10.3% for Medicare. Excluding Medicare patients, the use of no chemotherapy (as compared with the other options of NAC and aCT) was highest at 62.8% among public/ Medicaid insured patients. Use of NAC, aCT and no chemotherapy also varied by age (Fig. 2) . Over time, chemotherapy use decreased slightly in the 40 to 49 and 50 to 64 age groups, whereas increasing in the 65 years and older cohort and most notably in females under 40 years.
Use of Surgical Procedures After NAC
Overall, 41.5% of all females treated during this study period underwent either ULM or BLM (Table 2) . However, the mastectomy
Independent Predictors of Neoadjuvant Chemotherapy Use
On multivariable analysis, factors significantly associated with receiving NAC (Fig. 4) To address the missing data on HER2, a crucial treatment biomarker, a sensitivity analysis was performed including only cases with known HER2 status. Reassuringly, similar results were noted for the whole cohort. In a model limited to cases of known HER2 status, HER2-positivity was significantly associated with receipt of NAC (OR 1.56, CI 1.47-1.65, data not shown).
Ethnicity and race were not factors in NAC use except for small effects among Hispanics versus Non-Hispanic (NH) White (OR 1.09, CI 1.03-1.15). NAC treatment was also associated with unmarried status, public/Medicaid or lack of insurance, and care at a NCI-designated cancer center (OR 1.69, CI 1.58-1.82), and inversely associated with residence in a rural versus urban MSSA and care at a hospital with proportionally more lower SES patients. 
Independent Predictors of Surgical Treatment Use After Neoadjuvant Chemotherapy
On multivariable analysis (Table 3) , the only factors independently associated with having BCS instead of ULM after NAC were care at an NCI-designated cancer center (OR 1.28, CI 1.10-1.49), and more recent diagnosis. Factors independently associated with receiving BLM instead of ULM after NAC were young age (<40 yrs vs 50-64 yrs: OR 2.59, CI 2.21-3.03), high nSES (top vs bottom quintile: OR 2.10, CI 1.67-2.64), and more recent time period of diagnosis (2012 vs 1998: OR 8.66, CI 5.38-13.9).
DISCUSSION
In the large, diverse population of California, overall use of NAC among BC patients who received chemotherapy increased steadily over time to 18% to 20% from 2011 to 2012 and was highly associated with the age of patients. These observations are consistent with recent studies of the National Cancer Database (NCDB) that reported 17% to 23% NAC use among chemotherapy recipients. 1, 20, 21 We found that greater NAC use was also associated with NCI-designated cancer centers. Our most striking finding was that NAC recipients had the highest rates of BLM. Arguments in favor of NAC include earlier initiation of systemic treatments to address micrometastatic disease, and down-staging of tumor in the breast and axillary nodes. 8, 10, 22 A decision to undergo CPM, in addition to ULM, runs counter to one of NAC's primary benefits: to preserve the breast. Moreover, the higher cancer stage among most NAC patients (compared with aCT patients and those not treated with chemotherapy) suggests that development of distant metastasis is a greater risk than developing a metachronous contralateral primary cancer. Our results raise questions about which goals drive NAC use in the real-world setting, and warrant further investigation of the quality of such care.
Other studies have investigated patterns of NAC use, most recently in the NCDB; the authors reported a similar NAC rate as we observed, and also found statewide variation in NAC use (with California approximately in the middle among all states). Our findings of greater NAC use by young patients, racial/ethnic minorities, and academic centers are also consistent with prior studies. 20, 21 Our current study contributes a novel, real-world view of NAC utilization and subsequent surgical procedures, taking advantage of the CCR's comprehensive recording of cancer cases in the nation's most populous, most racially/ethnically diverse state. Consistent with practice guidelines, NAC use increased with cancer stage and adverse prognostic factors. Surprisingly, low SES, including residence in a low SES neighborhood, diagnosis in a hospitals with greater prorportion of lower SES patients, and having public/ Medicaid insurance, were associated with more NAC use, perhaps consistent with a propensity for later-stage presentation or biologically more aggressive disease. Lower NAC use among patients in rural regions may reflect lower access to facilities performing NAC and/or difficulty with repeated travel to a hospital for care. Predictably, NCI-designated centers had higher NAC use, consistent with their mission of innovation, clinical trial participation, and adoption of new guidelines. 11, 12 NAC was first developed for advanced BC cases. The use of breast conservation after disease down-staging with NAC was addressed in the seminal neoadjuvant therapy trial, NSABP B-18.
3 A recent NCDB study found a correlation between NAC use and BCS, although only among tumors larger than 3 cm.
1 By contrast, we found that the predictors of receiving either BCS or BLM (rather than the most common surgical procedure, ULM) after NAC were not clinical cancer prognostic factors but instead were the 
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Bilateral Mastectomy and Neoadjuvant Therapy sociodemographic characteristics of patients and hospitals. Other than more recent diagnosis, the sole predictor of post-NAC BCS was care at a NCI-designated cancer center, and the predictors of post-NAC BLM were younger age and high neighborhood SES. These results indicate that post-NAC surgical decisions were influenced by nonclinical factors (eg, age, NCI-designation status, and neighborhood SES). Our finding that post-NAC surgery was primarily associated with sociodemographic and hospital factors also prompts questions about care variability in different settings, available specialty services, and whether patients are uniformly presented with all available treatment options. For example, lower rates of BCS after NAC were recorded at non-NCI-designated cancer centers. This may indicate persistent conservative management attitudes at such centers, with surgeons favoring mastectomy for patients presenting with large palpable tumors, especially T3 lesions. Moreover, surgeons have disagreed on whether the entire tumor bed should be resected after NAC (which would favor more extensive surgery) or whether resection should focus only on the residual disease.
CPM, not an increase in synchronous bilateral BC, accounts for the notable rise in BLM rates reported in this study and others. 15, 16 In the case of BLM, the CCR lacks data on how often postmastectomy reconstruction was employed, a metric which could inform understanding of the sophistication and services available in treating facilities. Many explanations have been proposed for rising BLM rates, ranging from fear of a second cancer to a preference for cosmetic symmetry that BLM may best enable. 23 Despite its rising use, however, CPM does not reduce mortality in most patients. 16 Our findings thus identify BLM use after NAC as a potential target for initiatives to improve the quality of BC care. An important step towards quality improvement will be to determine whether there is any survival benefit of one surgical procedure over another (BCS vs ULM vs BLM) among complete versus partial responders to NAC.
Several factors warrant consideration in interpreting our results. Notably, SEER reports only the highest stage. Therefore, the recorded stage for NAC recipients is usually clinical (before any treatment) as it was in 63.8% of our cases, whereas for those who receive surgery before systemic therapy the recorded stage is usually pathological. This systematic difference in staging method between aCT and NAC patients may introduce bias. Given SEER's protocol for stage reporting, it is not possible to identify cases that were downstaged by the use of NAC, nor to determine whether the degree of response to NAC is associated with the choice of surgical procedure. It is reassuring, however, that the proportion of patients treated with NAC that we report here was similar to data from NCDB which does distinguish between methods and timing of staging.
1 Another limitation is that prevalence of family cancer history and BRCA1/2 mutations are not collected by cancer registries; these factors clearly influence decisions in favor of BLM. Further limitations are the lack of information on tumor response to NAC, which could be corrected by adoption of clinically relevant yp staging criteria across SEER registries, 24 and the absence of patient-reported and physicianreported data on the opinions that shaped treatment decisions. Our work has several notable strengths. California is the most populous and diverse state in the nation, and NAC usage falls in the middle among US regions. 21 As the population-based CCR encompasses all of California, selection bias was minimized and our results have broad relevance. Using CCR data allowed us to examine additional patient, hospital, and neighborhood characteristics that are unavailable from other population-based US cancer registry datasets.
In conclusion, the rate of BLM increased nearly 4-fold in California over the 15 years of our study period, whereas NAC use tripled. The FDA's recent endorsement of NAC as a tool to measure drug effectiveness and as a surrogate for systemic response is likely to increase NAC use. 11, 12 How these changing patterns in the timing of systemic therapy affect future surgical treatments should be monitored, particularly as we found that sociodemographic characteristics of patients and hospitals, not clinical prognostic factors, were the primary predictors of surgery type after NAC. This association of post-NAC surgery with social rather than clinical factors raises concern for societal disparities in access to different surgical options. The impact of surgical procedures on survival and other clinically relevant outcomes after NAC must be studied, as a step toward quality improvement in the use of NAC and subsequent surgery for early-stage breast cancer. 
